阿片类药物需要量的估算方法及应用进展

doi:10.19803/j.1672-8629.20230607

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (5): 519-523.
DOI: 10.19803/j.1672-8629.20230607

• 阿片类药物合理使用专栏 • 上一篇下一篇

阿片类药物需要量的估算方法及应用进展

李文鹏¹, 周虎子威¹, 朱兰², 王胜锋^1,*

¹北京大学公共卫生学院,重大疾病流行病学教育部重点实验室（北京大学）,北京 100191;
²国家药品监督管理局药品评价中心,国家药品监督管理局药物警戒研究与评价重点实验室,北京 100076

收稿日期:2023-09-27 出版日期:2024-05-15 发布日期:2024-05-13
通讯作者: ^*王胜锋,男,博士,研究员,药物流行病、真实世界数据分析和大数据建模。E-mail: shengfeng1984@126.com
作者简介:李文鹏,男,在读本科,预防医学。
基金资助:
国家自然科学基金资助项目（82173616）

Applications and progress of methods for estimating opioids requirements

LI Wenpeng¹, ZHOU Huziwei¹, ZHU Lan², WANG Shengfeng^1,*

¹Peking University School of Public Health, Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing 100191, China;
²Center for Drug Reevaluation, NMPA/NMPA Key Laboratory for Research and Evaluation of Pharmacovigilance, Beijing 100076, China

Received:2023-09-27 Online:2024-05-15 Published:2024-05-13

摘要/Abstract

摘要： 目的梳理阿片类药物需要量的估算方法应用现状和问题,为推进合理用药、改善估算方法提出建议。方法检索中国知网、万方数据、PubMed、国际麻醉品管制局有关文件,对纳入文献进行汇总和分析。结果目前国际上估算阿片类药物需求量主要有3种方法,3种方法对数据要求各不相同,各有优缺点。结论结合现存问题,建议监管部门投入更多资源,持续改善估算方法规则制定和药物数据记录质量;完善药物估算制度,促进阿片类药物的合理使用。

关键词: 阿片类药物, 需要量, 估计数制度, 需要量估计, 合理用药, 监管

Abstract: Objective To sort out the current status and existing problems in the application of estimation methods for opioid requirements, and to make suggestions for promoting the rational use of medication and improving estimation methods. Methods The related literature and documents from CNKI, Wanfang Data, PubMed, International Narcotics Control Boardwere were searched and analysed. Results There are three main methods for estimating opioid demand in the international arena, which have different data requirements and their own advantages and disadvantages. Conclusion In the context of existing problems, it is recommended that the regulator invest more resources to continuously improve the development of rules for estimation methods and the quality of drug data records and improve the drug estimation system in order to promote the rational use of opioids.

Key words: opioids, requirements, system of estimates, estimation of requirements, rational drug use, supervision

中图分类号:

R971
R954

李文鹏, 周虎子威, 朱兰, 王胜锋. 阿片类药物需要量的估算方法及应用进展[J]. 中国药物警戒, 2024, 21(5): 519-523.

LI Wenpeng, ZHOU Huziwei, ZHU Lan, WANG Shengfeng. Applications and progress of methods for estimating opioids requirements[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 519-523.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.zgywjj.com/CN/10.19803/j.1672-8629.20230607

https://www.zgywjj.com/CN/Y2024/V21/I5/519

参考文献

[1] YOO M, PERRET D, DUSTO N, et al.Pain and addiction: the distribution of supply and demand during the opioid epidemic[J]. Am J Phys Med Rehabil, 2022, 101(7): 702-707.
[2] ZHANG L, HUANG XX, LIU KK, et al.Research progress of opioid management in China[J]. Oncology Pharmacy(肿瘤药学), 2023, 13(1): 17-22.
[3] TIAN Y, XU ZY, GUAN XD, et al.Analysis of opioid use in China from 2014 to 2016[J]. Chinese Pharmacy(中国药房), 2019, 30(9): 1153-1157.
[4] International Narcotics Control Board. Guidelines for Estimating International Controlled Drugs(国际管制药物估算指南)[M]. New York: English, Publications and Books Section, United Nations Office at Vienna, 2012.
[5] International Narcotics Control Board. Report of the International Narcotics Control Board 2022(国际麻醉品管制局2022年报告)[R]. New York: English, Publications and Books, United Nations Office at Vienna, 2023.
[6] CLARK J, CROWTHER L, JOHNSON MJ, et al.Calculating worldwide needs for morphine for pain in advanced cancer and proportions feasibly met by country estimates of requirements and consumption. retrospective, time-series analysis (1997-2017)[J]. PLOS Glob Public Health, 2022, 2(7): 533.
[7] GOODMAN-MEZA D, FRIEDMAN J, KALMIN MM, et al.Geographical and socioeconomic disparities in opioid access in Mexico, 2015-19: a retrospective analysis of surveillance data[J]. Lancet Public Health, 2021, 6(2): e88-e96.
[8] HUANG Z, SU X, DIAO Y, et al.Clinical consumption of opioid analgesics in China: a retrospective analysis of the national and regional data 2006-2016[J]. J Pain Symptom Manage, 2020, 59(4): 829-835.
[9] CONNOR S, SISIMAYI C, DOWNING J, et al.Assessment of the need for palliative care for children in South Africa[J]. Int J Palliat Nurs, 2014, 20(3): 130-134.
[10] AZUMA K, ABE H, HOZUMI J, et al.Prefectural adequacy of opioid availability for cancer pain and its determinants in Japan: a preliminary study[J]. JMA J, 2020, 3(4): 340-346.
[11] YANG SL, WOON YL, TEOH CCO, et al.Adult palliative care 2004-2030 population study: estimates and projections in Malaysia[J]. BMJ Support Palliat Care, 2022, 12(e1): e129-e136.
[12] ETKIND SN, BONE AE, GOMES B, et al.How many people will need palliative care in 2040? past trends, future projections and implications for services[J]. BMC Med, 2017, 15(1): 102.
[13] REJAS-GUTIERREZ J, SICRAS-MAINAR A, DARBÀ J.Future projections of opioid use and cost in patients with chronic osteoarthritis pain in Spain[J]. Ther Adv Musculoskelet Dis, 2021, 13: 1-19.
[14] DZOTSENIDZE P, MAURER MA, KORDZAIA D, et al.The contribution of the international pain policy fellowship in improving opioid availability in Georgia[J]. J Pain Symptom Manage, 2017, 54(5): 749-757.
[15] FORTUNA D, CASELLI L, BANCHELLI F, et al.How many cancer patients need palliative care? a population-based study[J]. J Pain Symptom Manage, 2022, 63(4): 468-475.
[16] TREISH IM, HAMMOUDEH SS, SALMANY SS, et al.Should INCB consumption data be utilized to guide opioids policy?[J]. J Pain Symptom Manage, 2022, 63(5): e481-e487.
[17] BÄCKRYD E, HEILIG M, HOFFMANN M. Opioid availability statistics from the International Narcotics Control Board do not reflect the medical use of opioids: comparison with sales data from Scandinavia[J]. Scand J Pain, 2021, 21(4): 696-706.
[18] NESOFF ED, MARTINS SS, PALAMAR JJ.Caution is necessary when estimating treatment need for opioid use disorder using national surveys[J]. Am J Public Health, 2022, 112(2): 199-201.
[19] CLARK J, GNANAPRAGASAM S, GREENLEY S, et al.Perceptions and experiences of laws and regulations governing access to opioids in South, Southeast, East and Central Asia: a systematic review, critical interpretative synthesis and development of a conceptual framework[J]. Palliat Med, 2021, 35(1): 59-75.
[20] SEYA MJ, GELDERS SF, ACHARA OU, et al.A first comparison between the consumption of and the need for opioid analgesics at country, regional, and global levels[J]. J Pain Palliat Care Pharmacother, 2011, 25(1): 6-18.
[21] ZHI NJ, WEI XM, GAO X, et al.Analysis of clinical use of opioid analgesics in China[J]. Journal of Pharmacoepidemiology(药物流行病学杂志), 2018, 27(6): 400-405.
[22] RICE J, KANNAN AM, CASTRIGNANÒ E, et al.Wastewater-based epidemiology combined with local prescription analysis as a tool for temporalmonitoring of drugs trends - a UK perspective[J]. Sci Total Environ, 2020, 735: 1-13.
[23] International Narcotics Control Board. Report of the International Narcotics Control Board 2014(国际麻醉品管制局2014年报告)[R]. New York: English, Publications and Books, United Nations Office at Vienna, 2015.
[24] International Narcotics Control Board. Progress in Ensuring Adequate Supplies of Internationally Controlled Drugs for Medical and Scientific Purposes[R]. New York: English, Publications and Books, United Nations Office at Vienna, 2019.
[25] LIU Y, WU XM, GU JQ.The development of narcotic drug supervision in China and its external enlightenment[J]. Chinese Journal of New Drugs(中国新药杂志), 2015, 24(22): 2540-2543, 2554.
[26] NMPA.The Annual Report on National Drug Abuse Monitoring (2016)[EB/OL]. (2017-08-11)[2024-02-23]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20170811104001233.html.
[27] XIE LX, DENG YP, SHI LW.Opioid abuse crisis in the United Stataes and analgesic use and regulation in China[J]. Chinese Journal of Drug Abuse Control(中国药物滥用防治杂志), 2020, 26(4): 192-197.

阿片类药物需要量的估算方法及应用进展

Applications and progress of methods for estimating opioids requirements

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	李文鹏, 刘明煜, 曹颖, 周虎子威, 王胜锋. 阿片类药物全球滥用的监管现状及研究进展[J]. 中国药物警戒, 2024, 21(5): 513-518.
[2]	仇景辉, 周虎子威, 曹颖, 李文鹏, 王胜锋. 阿片类药物需要量的影响因素及干预措施研究进展[J]. 中国药物警戒, 2024, 21(5): 524-528.
[3]	曹颖, 周虎子威, 朱兰, 王胜锋. 复方甘草口服溶液的应用现状及思考[J]. 中国药物警戒, 2024, 21(5): 529-534.
[4]	刘翠丽, 吴晨, 王涛. 吡拉西坦制剂安全性风险分析及思考[J]. 中国药物警戒, 2024, 21(5): 563-566.
[5]	余馨, 贡磊磊, 姚伟洁, 袁偲偲, 冯欣. 中成药治疗复发性流产的临床研究概况性综述[J]. 中国药物警戒, 2024, 21(4): 361-365.
[6]	马美英, 赵晓佩, 张梦瑶, 胡一琳. 我国药品追溯码编码制度研究探讨[J]. 中国药物警戒, 2024, 21(2): 167-172.
[7]	范凯凯, 王聪, 刘洪峰, 王西勇. 临床药师对某院丙氨酰谷氨酰胺注射液应用干预分析[J]. 中国药物警戒, 2024, 21(2): 181-184.
[8]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[9]	刘敏, 陈艳, 刘文东, 王海学. 药物临床试验期间安全性数据快速报告的更新与思考[J]. 中国药物警戒, 2024, 21(1): 98-101.
[10]	黎杏仁, 沈爱宗, 苏丹. 质子泵抑制剂预防胆胰外科围术期应激性黏膜病变的合理性评价[J]. 中国药物警戒, 2023, 20(9): 1022-1026.
[11]	史香芬, 孙志勇, 张旭锋, 卢晓静, 杜书章, 张晓坚. 基于智能信息管理系统的门诊麻精药品全流程管理[J]. 中国药物警戒, 2023, 20(8): 899-903.
[12]	霍艳飞, 田月洁, 许莉莉, 谢彦军, 常虹, 孙春晓, 李霞. 535例氢溴酸高乌甲素制剂新的和严重的药品不良反应报告分析[J]. 中国药物警戒, 2023, 20(8): 921-926.
[13]	杨乐, 夏东胜, 王涛. 维生素B₆注射剂安全性风险分析[J]. 中国药物警戒, 2023, 20(7): 791-794.
[14]	孟康康, 刘赛月. 辅酶Q10注射剂上市后安全性分析[J]. 中国药物警戒, 2023, 20(7): 795-798.
[15]	刘婧, 夏亮, 张世杰. 1例多元药物过敏急性胰腺炎患者行药物激发试验的药学监护[J]. 中国药物警戒, 2023, 20(7): 822-824.